GSK's new CEO Luke Miels has quickly moved to back up GSK's strategy with major acquisitions, including a $2.2 billion buyout of RAPT Therapeutics and a $11 billion acquisition of Nuvalent, both announced within weeks of his taking over as CEO on January 1, 2026. These deals are part of Miels's stated plan to target bolt‑on M&A in the $2–4 billion range that fill gaps in GSK's respiratory, allergy, oncology, and immunology pipelines, often using assets whose science is already validated but where the current product has liabilities. The Nuvalent acquisition, in particular, is being positioned as a signature move that signals GSK's ambition to become a stronger player in cancer; the company is paying around $11–$10.6 billion for Nuvalent's two lung‑cancer candidates and a dual‑acting therapy in development, giving investors a 26–40% premium to the prior share price. Miels told analysts that he is looking for deals that are "hiding in plain sight,...
- Get link
- X
- Other Apps